Proteome Analysis of Differential Protein Expression in Cervical Cancer Cells after Paclitaxel Treatment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there is little information regarding the antineoplastic mechanism of paclitaxel against cervical carcinoma cells. We thus tried to analyze differential protein expression and antineoplastic mechanism-related proteins after paclitaxel treatment on cervical cancer cells by using a proteomic analysis and to investigate the mechanism of action. Materials and Methods: Using proteomics analysis including 2-DE and MALDI-TOF-MS, we detected the antineoplastic mechanism-related proteins. Then, we performed western blot analysis for apoptosis- and transformation- related proteins to confirm expression patterns derived from proteome analysis after paclitaxel treatment. Results: We identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells using proteomics methods. Paclitaxel treatment elevated main-ly apoptosis, immune response and cell cycle check point- related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Also, in the HPV-associated cervical carcinoma cells, paclitaxel demonstrated anti-proliferative activity through the membrane death receptor-mediated apoptotic pathway and the mitochondrial-mediated pathway. Conclusion: Identification and characterization of functionally modulated proteins involved in anti-cancer regulatory events should lead to a better understanding of the long-term actions of paclitaxel at the molecular level and will contribute to the future development of novel therapeutic drug treatments based upon current therapies.(Cancer Res Treat. 2004;36:395-399)
Abstract
Purpose: It is well known that infection with HPV (human papillomavirus) is the main cause of cervical cancer and certain types of HPV are recognized as carcinogens. At present, there is little information regarding the antineoplastic mechanism of paclitaxel against cervical carcinoma cells. We thus tried to analyze differential protein expression and antineoplastic mechanism-related proteins after paclitaxel treatment on cervical cancer cells by using a proteomic analysis and to investigate the mechanism of action. Materials and Methods: Using proteomics analysis including 2-DE and MALDI-TOF-MS, we detected the antineoplastic mechanism-related proteins. Then, we performed western blot analysis for apoptosis- and transformation- related proteins to confirm expression patterns derived from proteome analysis after paclitaxel treatment. Results: We identified several cellular proteins that are responsive to paclitaxel treatment in HeLa cells using proteomics methods. Paclitaxel treatment elevated main-ly apoptosis, immune response and cell cycle check point- related proteins. On the other hand, paclitaxel treatment diminished growth factor/oncogene-related proteins and transcription regulation-related proteins. Also, in the HPV-associated cervical carcinoma cells, paclitaxel demonstrated anti-proliferative activity through the membrane death receptor-mediated apoptotic pathway and the mitochondrial-mediated pathway. Conclusion: Identification and characterization of functionally modulated proteins involved in anti-cancer regulatory events should lead to a better understanding of the long-term actions of paclitaxel at the molecular level and will contribute to the future development of novel therapeutic drug treatments based upon current therapies.(Cancer Res Treat. 2004;36:395-399)
참고문헌 (25)
- "Docetaxel versus paclitaxel for antiangiogenesis", 11, pp.103~118 (2002)
- "Inhibition of endothelial cell function invitro and angiogenesis in vivo by docetaxel associationwith impaired repositioning of the microtubuleorganizing center", 1, pp.1191~1200 (2002)
- "Docetaxel (Taxotere) in combination withplatinums in patients with non-small cell lung cancer: trial dataand implications for clinical management", 28, pp.10~14 (2001)
- "Docetaxel (Taxotere) plus trastuzumab(Herceptin) in breast cancer", 28, pp.38~44 (2001)
- "Recent progress in the clinical developmentof docetaxel (Taxotere).", 26, pp.32~36 (1999)
- "Preclinical antitumor activityof two novel taxanes", 47, pp.97~105 (2001)
- "The isolation and structure of taxol anovel antileukemic and antitumor agent from Taxus brevifolia", pp.2325~7 (1971)
- "Differentialsensitivity of Taxol-induced Apoptosis in U2OS and SaOS2Osteogenic Sarcoma Cells", 35, pp.148~153 (2003)
- "Bcl-2 down-regulation is a novel mechanismof paclitaxel resistance", 64, pp.51~58 (2003)
- "Bcl-2 and bax expression in advanced non-small celllung cancer:lack of correlation with chemotherapy responseor survival in patients treated with docetaxel plus vinorelbine", 39, pp.139~143 (2003)
- "Bcl-2 and Bcl-xL are important for theinduction of paclitaxel resistance in human hepatocellular carcinomacells", 315, pp.771~779 (2004)
- "Paclitaxelincreases p21 synthesis and accumulation of its AKTphosphorylatedform in the cytoplasm of cancer cells", 22, pp.3260~3268 (2003)
- "Susceptibility to drug-induced apoptosis correlates with differentialmodulation of Bad,Bcl-2 and Bcl-xL protein levels", 7, pp.574~586 (2000)
- "MyD88 is involved in the signalling pathway forTaxol-induced apoptosis and TNF-alpha expression in humanmyelomonocytic cells", 118, pp.638~645 (2002)
- "Update on the antitumor activity of paclitaxel in clinicaltrials", 28, pp.28~ (1994)
- "Taxane AntineoplasticAgents", pp.31~57 (1995), ACS
- "Taxol-a novelinvestigational antimicrotubule agent", 82, pp.1247~59 (1990)
- "Microtubule stabilization by taxolinhibits initiation of DNA synthesis by thrombin and epidermalgrowth factor", 27, pp.341~50 (1981)
- "Modulation of microtubuledynamics by drugs a paradigm for the actions of cellularregulators", 24, pp.329~335 (1999)
- "Mechanism ofmitotic block and inhibition of cell proliferation by taxol atlow concentrations", 90, pp.9552~6 (1993)
- "Induction of survivinexpression by taxol (paclitaxel) is an early event ,which isindependent of taxol-mediated G2", M arrest, 2004, pp.279, 15196~15203
- "Proteomics revealsprotein profile changes in doxorubicin-treated MCF-7 humanbreast cancer cells", 181, pp.95~107 (2002)
- "Pharmacoproteomic analysis of prechemotherapyand postchemotherapy plasma samples from patientsreceiving neoadjuvant or adjuvant chemotherapy for breastcarcinoma", 100, pp.1814~1822 (2004)
- "Proteomic profiling drug-induced apoptosis in nonsmallcell lung carcinoma:identification of RS", DJ-1 andRhoGDIalpha, 2003, pp.63, 6928~6934
- "A prototype methodology combining surface-enhancedlaser desorption", ionization protein chip technology andartificial neural network algorithms to predict the chemoresponsivenessof breast cancer cell lines exposed to Paclitaxeland Doxorubicin under in vitro conditions, 2003, pp.3, 1725~1737